Skip to main content
. 2022 Jun 8;5(6):e2216199. doi: 10.1001/jamanetworkopen.2022.16199

Figure 3. Comparison of Posttreatment Outcomes of Treatment Groups .

Figure 3.

A, Percentage of hospitalized patients, for patients treated with FOLFIRINOX (leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin) or gemcitabine plus nab-paclitaxel (Gem-Nab-P). The hospitalization rate was assessed for the full cohort (naive) and the inverse probability treatment weighting (IPTW) and matched cohorts. B, Percentage of hospitalized patients per ECOG performance status (PS) score. C, Mean total cost assessed for the full cohort (naive) and the IPTW and matched cohorts. D, Percentage of patients by cost groups and treatment group. Low indicates less than $2000; medium, $2000 to $10 000; high, greater than $10 000 to $50 000; and top, greater than $50 000.